<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article121</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/FAIR-HF" style="display:block; margin-bottom:10px;">FAIR-HF Original</a></li>
<h2><strong>FAIR-HF</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Iron Supplementation in Heart Failure with Reduced Ejection Fraction and Iron Deficiency".<br/>
<br/>
The New England Journal of Medicine. 2009. 361:2436-2448.<br/>
PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcomes<br/>
8.2Secondary Outcomes<br/>
9Funding<br/>
10Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with chronic heart failure, reduced left ventricular ejection fraction, and iron deficiency, does intravenous iron supplementation improve symptoms and quality of life?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with chronic heart failure, reduced ejection fraction, and iron deficiency, intravenous iron (ferric carboxymaltose) supplementation improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the latest updates, specific guidelines reflecting the results of this trial were not detailed, but might consider intravenous iron supplementation in heart failure patients with confirmed iron deficiency.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Total number of participants: 459<br/>
- Inclusion Criteria: Ambulatory patients with heart failure of NYHA functional class II or III, left ventricular ejection fraction ≤40% (NYHA class II) or ≤45% (NYHA class III), iron deficiency (ferritin &lt;100 μg per liter or 100-299 μg per liter if transferrin saturation &lt;20%), and hemoglobin 95-135 g per liter<br/>
- Exclusion Criteria: Uncontrolled hypertension, significant other heart disease, inflammation, or significantly impaired hepatic or renal function<br/>
- Baseline Characteristics: Demographically similar groups with respect to clinical and laboratory characteristics<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Ferric carboxymaltose: 200 mg intravenous iron weekly until iron repletion, then monthly for maintenance<br/>
- Saline (Placebo): Same regimen as ferric carboxymaltose<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- 50% of patients in the ferric carboxymaltose group reported improvements compared to 28% in the placebo group (odds ratio for improvement, 2.51; 95% CI, 1.75 to 3.61) according to the Patient Global Assessment at week 24<br/>
- 47% in the ferric carboxymaltose group had an NYHA functional class I or II at week 24 compared to 30% in placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71)<br/>
<br/>
Secondary Outcomes<br/>
- Improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments<br/>
- Rates of death, adverse events, and serious adverse events were similar between groups<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Sponsored by Vifor Pharma.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text available at NEJM.org<br/>
- ClinicalTrials.gov number, NCT00520780
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
